The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

Apretude, Descovy, Truvada, and a generic version of Truvada—often referred to as PrEP—are approved for men at high risk of acquiring HIV. By Lisa L. Gill Updated by Justin Krajeski About ...

The Scottish Medicines Consortium has approved the use of Gilead’s Truvada for use in preventing new HIV infections, so called pre-exposure prophylaxis (PrEP). The decision has been hailed as a ...

Gilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending a priority review voucher (PRV) to set up a verdict within six months.

Two oral PrEP medications have been approved by the U.S. Food and Drug Administration (FDA)—Truvada and Descovy—and one injection drug called Apretude that must be taken once every two months.

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP). The government was ...

Truvada for PrEP, the name-brand version of the pill form of HIV prevention medication, was approved by the Food and Drug Administration in July 2012 for sexually active adults after having been ...

In this month’s issue, the Sexpert advises readers on how to navigate discussions of PrEP and sexual health while in the ...

At issue was a battle over patents for Truvada and a newer, upgraded version called Descovy — two highly effective and lucrative medications — as well as the role played by the federal ...

Gilead has maintained that it fully compensated the CDC for its contributions to the development of Truvada for PrEP while the government had argued that Gilead did not properly acknowledge or ...

When taken regularly, pre-exposure prophylaxis medications like Truvada and Descovy offer significant protection to uninfected people. According to the CDC, PrEP can reduce the risk of sexual ...